Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

Fluidigm Singapore Pte. Ltd.

Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. *

 

Period Start 2014-01-30 existent
  Group Fluidigm (Group)
Products Industry single cell analysis
  Industry 2 cell analysis technology
     
Region Region Singapore (cl=5)
  Country Singapore
  Street 5 Ang Mo Kio Avenue
Block 5008, #08-08
  City 569874 Singapore
  Tel +65-6858-7316
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Fluidigm (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top